Stock listing

NASDAQ:TTRX Turn Therapeutics Inc. Stock

Home listing (NASDAQ) of Turn Therapeutics Inc.

Follow Turn Therapeutics Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:TTRX

$8.10 USD -0.79 (-8.9%)

Close on Nov 20, 2026

Past year +198.7% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$7.93 – $9.20 USDNov 20, 2026
Volume
82,671 sharesNov 20, 2026
Market cap
$247.5M USDAt the close on Nov 20, 2026 · price × 30.57M shares outstanding
52-week range
$2.60 – $16.45 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$1.39M USDMedian day 96,205 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Turn Therapeutics Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:TTRX · Home$8.095 USD-0.795 (-8.9%)82,671$8.85$9.20$7.93$8.89Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:TTRX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$8.095-0.795-8.9%$8.85$9.20$7.9382,671
$8.89+0.34+4.0%$8.19$9.43$8.1952,416
$8.550.000.0%$8.75$9.105$8.09126,358
$8.55-0.795-8.5%$9.20$9.635$8.20148,595
$9.345-0.785-7.7%$10.25$10.28$9.2892,172
$10.13-0.44-4.2%$10.49$10.50$9.99598,771
$10.57+0.65+6.6%$10.11$11.18$10.1156,969
$9.92+0.13+1.3%$9.72$10.22$9.5288,089
$9.79+0.31+3.3%$8.795$9.855$8.45135,954
$9.48+0.54+6.0%$9.13$9.69$8.7898,132
$8.94-0.86-8.8%$9.66$10.19$8.30133,059
$9.80+0.29+3.0%$9.77$10.11$9.64593,967
$9.51-0.14-1.5%$9.65$10.33$9.455118,255
$9.65-0.78-7.5%$10.48$10.48$9.6585,806
$10.43-0.29-2.7%$10.45$10.54$9.60136,825
$10.72-0.40-3.6%$10.86$11.31$10.65137,690
$11.12+0.70+6.7%$10.48$11.55$10.2848,801
$10.42-0.19-1.8%$10.49$10.83$10.1098,414
$10.61+0.33+3.2%$10.16$10.82$10.0496,205
$10.28+0.10+1.0%$10.59$10.79$10.0987,000
$10.18+0.03+0.3%$10.05$10.47$9.83113,100
$10.15-0.32-3.1%$10.61$10.72$10.1460,600
$10.47-0.27-2.5%$10.54$10.74$10.2876,900
$10.74+0.17+1.6%$10.72$10.87$10.6029,900
$10.57-1.02-8.8%$11.49$11.49$10.39105,600
$11.59+0.48+4.3%$10.85$11.89$10.8580,300
$11.11+0.51+4.8%$10.42$11.44$10.4253,400
$10.60-0.51-4.6%$11.12$11.40$10.26117,400
$11.11-0.89-7.4%$11.72$11.99$11.0345,900
$12.00+0.61+5.4%$11.34$12.00$11.30109,800
$11.39-0.71-5.9%$11.94$12.00$11.24110,100
$12.10+0.46+4.0%$11.58$13.05$11.31175,700
$11.64-0.72-5.8%$12.35$12.42$11.5774,800
$12.36-0.97-7.3%$13.18$13.18$12.00111,300
$13.33+0.02+0.2%$13.35$13.48$12.17136,300
$13.31-1.08-7.5%$14.25$14.25$13.02122,000
$14.39+0.98+7.3%$13.41$14.63$13.0288,700
$13.41+0.37+2.8%$13.04$13.89$12.8579,500
$13.04+0.55+4.4%$12.29$13.13$12.2976,700
$12.49-0.77-5.8%$13.24$13.68$12.3090,000
$13.26-0.25-1.9%$13.50$13.88$12.07244,900
$13.51-1.78-11.6%$15.30$15.65$13.50101,600
$15.29-0.05-0.3%$15.31$15.44$14.53122,500
$15.34+0.40+2.7%$15.05$15.56$13.59172,900
$14.94+1.12+8.1%$13.80$16.45$13.80929,900
$13.82+0.10+0.7%$13.65$14.50$13.65199,900
$13.72+0.26+1.9%$13.46$14.21$13.40150,300
$13.46+0.01+0.1%$13.37$13.85$13.2285,100
$13.45+0.76+6.0%$12.43$13.82$12.11131,500
$12.69-0.69-5.2%$13.30$14.25$12.63135,700
$13.38-0.37-2.7%$13.34$14.29$13.03125,100
$13.75+1.09+8.6%$12.61$14.39$12.58277,500
$12.66+2.86+29.2%$9.99$12.68$9.82320,500
$9.80-0.27-2.7%$9.975$10.50$9.7070,600
$10.07+0.40+4.1%$9.67$10.50$9.6782,500
$9.67-0.15-1.5%$9.70$10.25$9.00106,400
$9.82+0.22+2.3%$9.60$10.29$9.2843,200
$9.60-0.24-2.4%$9.83$10.25$9.5031,600
$9.84-0.27-2.7%$10.10$10.28$9.4762,800
$10.11+0.48+5.0%$9.54$10.25$9.5147,600
$9.63-0.10-1.0%$10.04$10.04$9.4569,200
$9.73+0.05+0.5%$9.78$10.04$9.5831,400
$9.68+0.22+2.3%$9.39$9.87$9.0470,300
$9.46-0.08-0.8%$9.635$9.925$9.3522,200
$9.54-0.28-2.9%$9.945$10.03$9.5232,000
Ticker
NASDAQ:TTRX
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Turn Therapeutics Inc. news

Turn Therapeutics Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
21 in the last 12 months · 31 in all · newest Nov 16, 2026 · oldest 2025
Decks
8 decks · latest Nov 10, 2026

Where Turn Therapeutics Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:TTRX · Home listing · This pageNASDAQUnited StatesUSD
BOATS:TTRXBOATSUnited StatesUSD

Valuation

Price/book 43.5× against a median of 1.2×: the highest of 11 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$244.2M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
43.5×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
1.1×
Beta vs S&P 500
1.54

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Turn Therapeutics Inc. · NASDAQ:TTRXUS$247.5MUS$244.2Mn/an/an/a43.5×n/a1.1×1.54
Eikon Therapeutics, Inc. · NASDAQ:EIKNUS$256.8MUS$44.67Mn/an/an/a0.7×n/a0.7×1.91
SAB Biotherapeutics, Inc. · NASDAQ:SABSUS$255.7MUS$156.5Mn/an/an/a1.2×n/a0.0×1.19
Evommune, Inc. · NYSE:EVMNUS$255.5MUS$86.86Mn/an/an/a1.0×n/a0.0×0.96
Editas Medicine, Inc. · NASDAQ:EDITUS$253.1MUS$119.7Mn/a2.4×n/a3.0×−144.9%0.7×2.22
Q32 Bio Inc. · NASDAQ:QTTBUS$249.6M−US$35.66M7.7×−0.7×−1.9×0.9×59.8%0.0×0.59
Mabpharm Limited · HKEX:2181US$247.3MUS$279.4M29.7×3.0×28.9×8.5×8.8%1.6×n/a
Lexeo Therapeutics, Inc. · NASDAQ:LXEOUS$245.1MUS$56.52Mn/an/an/a1.1×n/a0.0×1.62
Shandong Boan Biotechnology Company., Limited. Class H · HKEX:6955US$242.7MUS$93.26M227×0.8×4.7×0.6×0.9%0.0×n/a
Curocell, Inc. · KRX:372320US$241.3MUS$192.5Mn/an/an/a4.5×n/a0.2×n/a
Clinuvel Pharmaceuticals Limited · ASX:CUVUS$238.9MUS$73.38M10.3×1.1×2.6×1.3×36.0%0.0×n/a
Median of the othersUS$248.4MUS$90.06M20.0×1.1×3.6×1.2×8.8%0.0×1.41

Forecasts

2 strong buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
25.00 USD · Analysts' mean
EPS, year to Dec 2026
-0.46 · 2 analysts
Revenue, year to Dec 2026
250K · 2 analysts

Team and board

Officers

OfficerRole
Bradley BurnamChief Executive Officer
Sasha DamouniInvestor Relations / Media Contact
Sasha Damouni EllisCorporate Communications & IR Lead
Zuraiz ChaudharyChief Accounting Officer, VP Finance
Muhammad ZubairController
Neil GhodadraChief Medical Officer, Board Director
Robert RedfieldChief Scientific Officer
Stephen M. HahnExecutive Clinical and Regulatory Lead

Board

DirectorRole
Martin DewhurstDirector

Events

QuarterResultsShare move
Q3 2026Nov 9, 2026 · Before open+3.3%
Q2 2026Aug 12, 2026 · After close−6.5%
Q1 2026May 11, 2026 · After close+2.6%
Q4 2025Mar 31, 2026 · Before open−0.6%
Q3 2025Nov 13, 2025−9.1%
Q2 2025Sep 16, 2025

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (November 2026)Investor deck37 slidesNov 10, 2026
Investor Presentation (October 2026)Investor deck37 slidesOct 7, 2026
Investor Presentation (July 2026)Investor deck38 slidesJul 28, 2026
Investor Presentation (July 2026)Investor deck25 slidesJul 7, 2026
2026 Jefferies Global Healthcare ConferenceConference28 slidesJun 3, 2026
Investor Presentation (February 2026)Investor deck31 slidesFeb 9, 2026
Investor Presentation (January 2026)Investor deck27 slidesJan 7, 2026
Investor Presentation (September 2025)Investor deck24 slidesSeptember 2025

Open Decks

Financings

RaiseDate
Shares under existing share purchase agreement
Closed: raise
Use of proceeds: Strengthen the balance sheet and extend operating runway into late 2026 for clinical and strategic objectives
Jan 12, 2026

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022
Revenue000
Cost of revenue52.7K
Gross profit-52.7K
Research and development265.6K246.0K7.50K
Selling, general and administrative5.59M1.55M2.30M4.21M
Operating income-5.86M-1.80M-2.31M-4.21M
Depreciation and amortization52.7K47.5K43.9K52.7K
EBITDA-5.81M-1.75M-2.26M-4.16M
Interest expense85.4K
Income before tax-3.19M-1.77M-2.29M-4.29M
Income tax800
Net income-3.19M-1.77M-2.29M-4.29M
Earnings per share, basic-0.12-0.07-0.17-0.33
Earnings per share, diluted-0.12-0.07

Balance sheet

LineFY2025FY2024FY2023FY2022
Cash and equivalents4.03M498.3K1.18M2.10M
Current assets5.20M1.10M1.20M2.13M
Total assets12.2M2.05M2.01M2.91M
Accounts payable2.93M256.0K
Current liabilities6.00M707.9K489.8K1.72M
Total debt80.4K121.0K25.2K83.7K
Total liabilities7.48M2.23M1.93M1.76M
Shareholders' equity4.69M-177.4K85.8K1.16M
Shares outstanding29.4M26.8M13.2M13.2M

Cash flow

LineFY2025FY2024FY2023FY2022
Cash from operations-2.56M-1.36M-1.38M-1.24M
Capital spending-153.0K-99.5K-44.3K0
Free cash flow-2.72M-1.46M-1.42M-1.24M
Cash from investing-153.0K-99.5K-44.3K-17.7K
Cash from financing6.92M1.15M500.0K350.0K
Change in cash4.20M-308.4K-922.0K2.10M

Open Financials

Filings

FilingDateTypeFiled with
EFFECT · Notice that a registration is effectiveNov 17, 2026Other filingsSEC
EFFECT · Notice that a registration is effectiveNov 17, 2026Other filingsSEC
424B5 · ProspectusNov 16, 2026Offer documentSEC
424B3 · ProspectusNov 16, 2026Offer documentSEC
8-K · Current reportNov 10, 2026Current reportSEC
S-3 · Registration statementNov 9, 2026Offer documentSEC
S-3 · Registration statementNov 9, 2026Offer documentSEC
10-Q · Quarterly reportNov 9, 2026Quarterly reportSEC
8-K · Current reportNov 9, 2026ResultsSEC
ARS · Annual report to shareholdersOct 19, 2026Annual reportSEC
All 131 filings
FilingDateTypeFiled with
DEF 14A · Proxy statementOct 19, 2026Meeting noticeSEC
8-K · Current reportOct 6, 2026Current reportSEC
8-K · Current reportSep 10, 2026Current reportSEC
8-K · Current reportSep 9, 2026Current reportSEC
DAug 26, 2026Other filingsSEC
8-K · Current reportAug 18, 2026FinancingSEC
8-K · Current reportAug 17, 2026Current reportSEC
10-Q · Quarterly reportAug 12, 2026Quarterly reportSEC
8-K · Current reportAug 12, 2026ResultsSEC
8-K · Current reportJul 28, 2026Current reportSEC
8-K · Current reportJul 7, 2026Current reportSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
8-K · Current reportJun 3, 2026Current reportSEC
4 · Change in ownershipJun 1, 2026Insider tradeSEC
8-K · Current reportJun 1, 2026Current reportSEC
8-K · Current reportMay 27, 2026Current reportSEC
8-K · Current reportMay 19, 2026Current reportSEC
8-K · Current reportMay 18, 2026Current reportSEC
C-TRMay 12, 2026Other filingsSEC
10-Q · Quarterly reportMay 11, 2026Quarterly reportSEC
8-K · Current reportMay 11, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeApr 6, 2026Big-stake noticeSEC
4 · Change in ownershipApr 3, 2026Insider tradeSEC
4 · Change in ownershipApr 3, 2026Insider tradeSEC
4 · Change in ownershipApr 3, 2026Insider tradeSEC
4 · Change in ownershipApr 3, 2026Insider tradeSEC
EFFECT · Notice that a registration is effectiveApr 3, 2026Other filingsSEC
EFFECT · Notice that a registration is effectiveApr 3, 2026Other filingsSEC
POS AM · Amendment to an effective registrationMar 31, 2026Offer documentSEC
POS AM · Amendment to an effective registrationMar 31, 2026Offer documentSEC
10-K · Annual reportMar 31, 2026Annual reportSEC
8-K · Current reportMar 31, 2026ResultsSEC
8-K · Current reportMar 24, 2026Material contractSEC
8-K · Current reportFeb 17, 2026Current reportSEC
8-K · Current reportFeb 9, 2026Current reportSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 4, 2026Insider tradeSEC
8-K · Current reportJan 12, 2026Current reportSEC
8-K · Current reportJan 7, 2026Management or board changeSEC
4 · Change in ownershipDec 12, 2025Insider tradeSEC
4 · Change in ownershipNov 25, 2025Insider tradeSEC
4 · Change in ownershipNov 24, 2025Insider tradeSEC
4 · Change in ownershipNov 21, 2025Insider tradeSEC
4 · Change in ownershipNov 17, 2025Insider tradeSEC
424B3 · ProspectusNov 17, 2025Offer documentSEC
424B3 · ProspectusNov 17, 2025Offer documentSEC
10-Q · Quarterly reportNov 13, 2025Quarterly reportSEC
8-K · Current reportNov 13, 2025ResultsSEC
8-K · Current reportNov 12, 2025Current reportSEC
8-K · Current reportNov 4, 2025Current reportSEC
8-K · Current reportOct 30, 2025Current reportSEC
4 · Change in ownershipOct 29, 2025Insider tradeSEC
424B5 · ProspectusOct 29, 2025Offer documentSEC
8-K · Current reportOct 28, 2025Material contractSEC
4 · Change in ownershipOct 23, 2025Insider tradeSEC
4 · Change in ownershipOct 23, 2025Insider tradeSEC
8-K · Current reportOct 22, 2025Current reportSEC
4 · Change in ownershipOct 10, 2025Insider tradeSEC
4 · Change in ownershipOct 10, 2025Insider tradeSEC
4 · Change in ownershipOct 10, 2025Insider tradeSEC
4 · Change in ownershipOct 10, 2025Insider tradeSEC
4 · Change in ownershipOct 10, 2025Insider tradeSEC
S-1 · Registration statementOct 9, 2025Offer documentSEC
424B4 · ProspectusOct 8, 2025Offer documentSEC
3 · Initial statement of ownershipOct 7, 2025Insider tradeSEC
3 · Initial statement of ownershipOct 7, 2025Insider tradeSEC
3 · Initial statement of ownershipOct 7, 2025Insider tradeSEC
3 · Initial statement of ownershipOct 7, 2025Insider tradeSEC
3 · Initial statement of ownershipOct 7, 2025Insider tradeSEC
3 · Initial statement of ownershipOct 7, 2025Insider tradeSEC
S-8 · Registration statement for employee plansOct 7, 2025Offer documentSEC
CERT · Exchange's certificate of listingOct 7, 2025Other filingsSEC
8-A12B/A · Registration of shares for listing on an exchange, amendedOct 7, 2025Other filingsSEC
8-K · Current reportOct 2, 2025Material contractSEC
EFFECT · Notice that a registration is effectiveOct 1, 2025Other filingsSEC
8-A12B · Registration of shares for listing on an exchangeSep 29, 2025Other filingsSEC
CORRESP · Letter to the SECSep 26, 2025Other filingsSEC
CORRESP · Letter to the SECSep 24, 2025Other filingsSEC
S-1/A · Registration statement, amendedSep 24, 2025Offer documentSEC
UPLOAD · Letter from the SECSep 23, 2025Other filingsSEC
1-SASep 22, 2025Other filingsSEC
CORRESP · Letter to the SECSep 16, 2025Other filingsSEC
S-1/A · Registration statement, amendedSep 16, 2025Offer documentSEC
UPLOAD · Letter from the SECSep 11, 2025Other filingsSEC
DRS · Draft registration statementSep 2, 2025Offer documentSEC
CORRESP · Letter to the SECAug 29, 2025Other filingsSEC
S-1 · Registration statementAug 29, 2025Offer documentSEC
UPLOAD · Letter from the SECAug 14, 2025Other filingsSEC
DRSLTR · Letter to the SEC with a draftJul 30, 2025Other filingsSEC
DRS/A · Draft registration statement, amendedJul 30, 2025Offer documentSEC
1-KJun 27, 2025Other filingsSEC
DRS · Draft registration statementJun 20, 2025Offer documentSEC
253G2Jun 13, 2025Other filingsSEC
C-ARApr 29, 2025Other filingsSEC
253G2Apr 22, 2025Other filingsSEC
253G2Apr 2, 2025Other filingsSEC
QUALIFApr 1, 2025Other filingsSEC
CORRESP · Letter to the SECMar 27, 2025Other filingsSEC
1-A/AMar 27, 2025Other filingsSEC
1-A/AMar 26, 2025Other filingsSEC
CORRESP · Letter to the SECMar 25, 2025Other filingsSEC
1-A/AMar 25, 2025Other filingsSEC
C-UMar 24, 2025Other filingsSEC
UPLOAD · Letter from the SECMar 24, 2025Other filingsSEC
CORRESP · Letter to the SECMar 18, 2025Other filingsSEC
1-A/AMar 18, 2025Other filingsSEC
UPLOAD · Letter from the SECMar 17, 2025Other filingsSEC
CORRESP · Letter to the SECMar 6, 2025Other filingsSEC
1-A/AMar 6, 2025Other filingsSEC
UPLOAD · Letter from the SECFeb 27, 2025Other filingsSEC
1-AJan 31, 2025Other filingsSEC
C/AJan 17, 2025Other filingsSEC
C/ADec 18, 2024Other filingsSEC
C-UNov 12, 2024Other filingsSEC
COct 22, 2024Other filingsSEC
C/AAug 19, 2024Other filingsSEC
C/AJul 15, 2024Other filingsSEC
CMay 22, 2024Other filingsSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Turn Therapeutics Inc.’s releases · as of Nov 6, 2026

Common shares
30,572,704
Fully diluted
30,572,704

Fully diluted

LineSharesAs of
Common shares30,572,704Nov 6, 2026

Share count over time

CountShares
Nov 6, 202630,572,704

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Vanguard466K1.5%US$6.71MSep 30, 2026
BlackRock259K0.85%US$3.73MSep 30, 2026
SteelPeak Wealth, LLC251K0.82%US$3.62MSep 30, 2026
Ieq Capital, LLC227K0.74%US$3.27MSep 30, 2026
Millennium168K0.55%US$2.41MSep 30, 2026
Geode Capital159K0.52%US$2.28MSep 30, 2026
Morgan Stanley140K0.46%US$2.01MSep 30, 2026
DDFG, Inc111K0.36%US$1.6MSep 30, 2026
Susquehanna94,0760.31%US$1.35MSep 30, 2026
Hrt Financial LP57,4500.19%US$826KSep 30, 2026
All 41 holders
HolderSharesOf the companyValueAs of
Aaron Wealth Advisors LLC32,5640.11%US$469KSep 30, 2026
Northern Trust30,7620.10%US$443KSep 30, 2026
Tamar Securities, LLC30,0000.10%US$432KSep 30, 2026
Goldman Sachs27,5100.09%US$396KSep 30, 2026
Bridgewater Advisors Inc.25,3260.08%US$226KSep 30, 2026
HighTower Advisors, LLC24,2790.08%US$349KSep 30, 2026
Brown Brothers Harriman & Co23,6880.08%US$341KSep 30, 2026
Schwab16,3100.05%US$235KSep 30, 2026
Jefferies Financial Group Inc.16,3000.05%US$235KSep 30, 2026
LPL Financial LLC16,1000.05%US$232KSep 30, 2026
McCarthy Asset Management, Inc.15,0180.05%US$216KSep 30, 2026
Jump Financial, LLC14,9440.05%US$215KSep 30, 2026
Bank of America14,1240.05%US$203KSep 30, 2026
Barclays13,7480.04%US$198KSep 30, 2026
ExodusPoint Capital Management, LP12,0980.04%US$174KSep 30, 2026
Schonfeld Strategic Advisors LLC11,2140.04%US$161KSep 30, 2026
Jane Street11,1310.04%US$160KSep 30, 2026
Qube Research & Technologies Ltd10,9410.04%US$157KSep 30, 2026
Cannon Financial Strategists, Inc.10,0000.03%US$144KSep 30, 2026
Composition Wealth, LLC10,0000.03%US$144KSep 30, 2026
Aster Capital Management (DIFC) Ltd5,2350.02%US$75,332Sep 30, 2026
Citigroup Inc4,7230.02%US$67,964Sep 30, 2026
TD3,0590.01%US$40,375Sep 30, 2026
Tower Research Capital LLC (TRC)2,671<0.01%US$38,435Sep 30, 2026
UBS2,627<0.01%US$37,803Sep 30, 2026
Blue Trust, Inc.1,122<0.01%US$16,146Sep 30, 2026
Wells Fargo1,000<0.01%US$14,390Sep 30, 2026
RBC408<0.01%US$6,000Sep 30, 2026
Pflug Koory, LLC170<0.01%US$2,446Sep 30, 2026
Caitong International Asset Management Co., Ltd15<0.01%US$216Sep 30, 2026
Parkside Financial Bank & Trust10<0.01%US$144Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund62,7490.21%US$458KJun 30, 2026
iShares Micro-Cap ETF36,2320.12%US$264KJun 30, 2026
Fidelity Nasdaq Composite Index Fund17,1420.06%US$89,138May 31, 2026
Vanguard Balanced Index Fund9,8970.03%US$72,248Jun 30, 2026
1290 VT Micro Cap Portfolio2,359<0.01%US$17,221Jun 30, 2026
Victory Extended Market Index Fund1,244<0.01%US$10,400Jul 31, 2026
Vanguard Institutional Total Stock Market Index Fund129<0.01%US$942Jun 30, 2026

Big stakes

StakeStakeSharesDateFiling
Bradley Burnam52.76%15.7MDec 31, 2025Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Andrew Gengos
Other companies: Immuneering Corporation (Chief Financial Officer and Treasurer · Since at least Jul 16, 2026); Terns Pharmaceuticals, Inc. (Chief Financial Officer · Since at least Feb 24, 2025); LeonaBio, Inc. (CFO and Chief Business Officer · May 18, 2023 – Sep 3, 2024 · Past); Cyteir Therapeutics Inc (Chief Business Officer · Jun 17, 2021 – Feb 22, 2022 · Past); Synlogic Inc (Chief Operating Officer · Oct 9, 2017 – Mar 14, 2018 · Past)
Director · Since at least Oct 7, 2025
Arthur Golden
Other companies: Emerson Electric Company (Director · Feb 7, 2023 – Nov 8, 2023 · Past)
Director · Since at least Oct 7, 2025
Andrew ScottVice President of Corporate Communications · Nov 4, 2025 – Nov 5, 2026 · Past
Bradley BurnamChief Executive Officer, Director · Since at least May 28, 2026
Kent KesterDirector · Since at least Oct 7, 2025
Martin DewhurstDirector · Since at least Mar 31, 2026
Muhammad ZubairController · Since at least Nov 4, 2026
Neil GhodadraChief Medical Officer, Board Director · Since at least Nov 4, 2026
Robert R. RedfieldChief Scientific Officer · Since at least Sep 9, 2026
Sasha DamouniInvestor Relations / Media Contact · Since at least Sep 10, 2026
All 13 people
PersonSeat
Sasha Damouni EllisCorporate Communications & IR Lead · Since at least Jul 6, 2026
Stephen M. HahnExecutive Clinical and Regulatory Lead · Since at least Aug 12, 2026
Zuraiz ChaudharyChief Accounting Officer, VP Finance · Since at least Oct 7, 2025

Open People

Log in to ask 6ix AI your own questions about Turn Therapeutics Inc.